Skip to main content
. 2010 Mar 22;107(14):6532–6537. doi: 10.1073/pnas.0913912107

Table 4.

Summary of TSS in CTCL biopsies taken from patients treated with PXD101, depsipeptide, or LBH589

TSS PR/SD PD Total
≥6 9 4 13
<6 4 4 8
Total 13 8 21

Distribution of patients categorized as having high (≥6) or low (<6) TSS for HR23B according to response to treatment (PR/SD) or no response (PD) in patients treated with PXD101, depsipeptide, or LBH589. Positive predictive value: 64.7%.